BAJAJ BROKING
AstraZeneca Pharma India received CDSCO approval to import and distribute Durvalumab (Imfinzi) for an additional cancer treatment. The drug will target NSCLC with chemotherapy in India, expanding its therapeutic applications
AstraZeneca Pharma India has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import and distribute Durvalumab (Imfinzi) for an additional indication in the Indian market. This approval will allow AstraZeneca to bring its cancer drug to patients who require specific treatments for non-small cell lung cancer (NSCLC) in combination with chemotherapy.
This development marks an important step in the company’s efforts to expand its portfolio of cancer treatments available in India.
Durvalumab, marketed as Imfinzi, is already used to treat certain types of cancer globally. The approval from CDSCO opens the door for the drug to be used in combination with chemotherapy as a neoadjuvant treatment. This will be followed by Durvalumab monotherapy after surgery, specifically for patients with resectable NSCLC that involves tumours 4 cm or larger, and node-positive cases.
The approval covers two dosage strengths: 120 mg/2.4 mL and 500 mg/10 mL solutions for infusion. This addition will provide more treatment options for cancer patients in India, helping to address cases where other treatments are ineffective.
The new indication focuses on patients with non-small cell lung cancer (NSCLC) who do not have known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. This specific group of patients with resectable tumours will benefit from the combination of Durvalumab and chemotherapy, as well as the continued use of Durvalumab post-surgery.
By expanding the range of its cancer drug treatments, AstraZeneca aims to strengthen its presence in India’s oncology market.
Following this announcement, shares of AstraZeneca Pharma India closed at ₹6,749 on the BSE, reflecting a 1.65% decline. Despite the drop, the company’s stock remains of interest as its ongoing advancements in the pharmaceutical sector continue to make headlines. The approval of Durvalumab for a new indication is expected to contribute to AstraZeneca’s growth in the Indian market.
This approval further establishes AstraZeneca’s commitment to improving cancer treatment options in India, reinforcing its standing in the country's pharmaceutical industry.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share Market Today | Indian Markets Eye Flat to Positive Opening
15 Oct, 2024 | 4 Min. read
JSW Infra Wins Bid for New Port in Maharashtra
15 Oct, 2024 | 2 Min. read
Maruti Suzuki Unveils New Baleno Regal Edition
15 Oct, 2024 | 2 Min. read
Sterling & Wilson Wins ₹823cr Order, Q2 Boost
15 Oct, 2024 | 2 Min. read
J Kumar Infra Secures ₹298 Crore Pune Order
15 Oct, 2024 | 2 Min. read
Commodities Market Today | Oil Drops on OPEC Outlook, Metals Also Fall
15 Oct, 2024 | 1 Min. read
Gold Rate Today | Gold Drops 0.3%, Silver Falls 0.8% in Market
15 Oct, 2024 | 2 Min. read
HDFC Life Q2 FY’2024-25 Results
15 Oct, 2024 | 3 Min. read
HAL Elevated To Maharatna Status For Greater Autonomy
14 Oct, 2024 | 2 Min. read
Oil Prices Dip As China Falls Short On Stimulus, Israel-Iran Tensions Rise
14 Oct, 2024 | 2 Min. read
JSW Energy Inks Deal For 1,500 MW Pumped Hydro Storage
14 Oct, 2024 | 2 Min. read
CCPA Directs Ola To Allow Refunds Via Bank Or Coupon
14 Oct, 2024 | 2 Min. read
RBI Launches ULI: Transforming Loan Access
August 27, 2024 | 4 Min. read
Textile Sector in India
September 20, 2024 | 5 Min. read
List of IPOs with DRHPs Filed
November 30, 2023 | 3 Min. read
Aditya Birla Group
September 28, 2023 | 10 Min. read
Bajaj Housing Finance Ltd IPO: Things Smart Investors Need to Know
September 05, 2024 | 4 Min. read
Budget Stock Ideas 2024-2025 | Stocks to Buy Today
July 24, 2024 | 4 Min. read
IPO Eligibility Criteria : Full Details
March 15, 2024 | 6 Min. read
What Is the Lock-In Period in IPOs?
October 18, 2023 | 6 Min. read
Godfrey Phillips Announces 2:1 Bonus Shares
September 16, 2024 | 7 Min. read
Jindal Group- A Comprehensive Analysis
September 27, 2024 | 7 Min. read
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading